Clinical Trials Browser

Malignant mesenchymal tumor × Irinotecan × 90 days × Clear all

NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Phase 2 Active not recruiting

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma